Mark Nuijten, PhD, MD, MBA
Mark Nuijten is medical doctor, health economist, and valuation economis and has position as Professor Valuation of Medical Innovation at Ben-Gurion University in Israel. Mark was Board Director of ISPOR and Chair of Management Board of Value in Health. He obtained his PhD in health economics at Erasmus University, Rotterdam.
Mark Nuijten is founder of A2M and a partner of Minerva International. He was trained as a physician before obtaining his international MBA from Erasmus University, Rotterdam, where he later was a senior staff member. Prior to setting up Ars Accessus Medica, Mark Nuijten was founding Managing Director of the IQVIA Quintiles office in Netherlands.
He is a pioneer in the field of healthcare innovation in biotechnology and has been the first classical health economist successfully applying and developing Discounted Cash Flow methodologies for valuation of biotechnology innovation, for example, a Pricing Model to assess prices of expensive orphan drugs from an investor’s perspective. Other innovative concepts are the development of a Pricing Matrix Model for research in early phase development and a Financial Valuation Algorithm for the assessment of the future positioning of a new, innovative medicinal product.
Mark Nuijten has contributed to many positive reimbursement decisions for innovative medications in Europe by institutions such as NICE.
Mark Nuijten, PhD, MD, MBA
Mark Nuijten is medical doctor, health economist, and valuation economis and has position as Professor Valuation of Medical Innovation at Ben-Gurion University in Israel. Mark was Board Director of ISPOR and Chair of Management Board of Value in Health. He obtained his PhD in health economics at Erasmus University, Rotterdam.
Mark Nuijten is founder of A2M and a partner of Minerva International. He was trained as a physician before obtaining his international MBA from Erasmus University, Rotterdam, where he later was a senior staff member. Prior to setting up Ars Accessus Medica, Mark Nuijten was founding Managing Director of the IQVIA Quintiles office in Netherlands.
He is a pioneer in the field of healthcare innovation in biotechnology and has been the first classical health economist successfully applying and developing Discounted Cash Flow methodologies for valuation of biotechnology innovation, for example, a Pricing Model to assess prices of expensive orphan drugs from an investor’s perspective. Other innovative concepts are the development of a Pricing Matrix Model for research in early phase development and a Financial Valuation Algorithm for the assessment of the future positioning of a new, innovative medicinal product.
Mark Nuijten has contributed to many positive reimbursement decisions for innovative medications in Europe by institutions such as NICE.